OCT 10, 2019 9:00 AM PDT

Next Generation Targets for Immuno-Oncology

Sponsored by: Bio-Techne
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Sr. Director, Protein Business Unit, R&D Systems
    Biography
      Anthony received his Ph.D. in Cell Biology and Anatomy at the University of Arizona where his research concentrated on understanding the molecular mechanisms of cardiac valve development. He moved onto a Postdoctoral Research Fellowship at the University of Minnesota where he utilized zebrafish and mouse model systems to uncover new genes involved in kidney and heart development and also published the genetic cause of the dwarfing syndrome in humans called dominant Robinow Syndrome. Anthony spent time in the Stem Cell biotech industry using mRNA overexpression to reprogram somatic cells to pluripotency as well as transdifferentiating one cell type into another. Finally, Anthony has been at R&D Systems for the last 8 years working as a Manager and then Director in the Protein Development Department. Anthony has over 12 years of Biotech industry experience and is focused on offering the highest quality recombinant proteins to customers. New protein product offerings in the Immuno-oncology area is a major focus for R&D Systems as so many academic and biotech/pharma labs are entering this area with the success of both antibody immunotherapy as well as CAR T or CAR NK research and therapies.

    Abstract

    Blockade of CTLA-4 and PD-1, members of the B7/CD28 family, have proven to be the most successful cancer immunotherapies to date. While the current therapeutic focus remains on B7/CD28 family members, novel immunoregulatory pathways are being uncovered as potential targets for oncology research and cancer immunotherapy. In this presentation, we discuss some of the next generation of novel immune checkpoint molecules, including Butyrophilins (BTNs), leukocyte immunoglobulin-like receptors (LILRs), and V-Set and Immunoglobulin domain containing (VSIGs). Specifically, we will present data demonstrating that bioactive recombinant Butyrophilin proteins (BTN1A1, BTN2A2, and BTN3A1) are T cell inhibitory modulators that inhibit cytokine secretion and cell proliferation on anti-CD3 activated T cells. We will also show data identifying ANGPTL proteins as novel LILR receptors and discuss a novel group of proteins termed V-Set And Immunoglobulin Domain-Containing (VSIG).


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    Loading Comments...
    Show Resources
    Attendees
    • See more